Low levels of BRCA1 protein expression predict a worse prognosis in stage I-II colon cancer.

IF 2.3 4区医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

International Journal of Biological Markers Pub Date : 2021-03-01 Epub Date: 2021-02-14 DOI:10.1177/1724600820986572

Changzheng Du, Yifan Peng, Yiping He, Guoan Chen, Hao Chen

{"title":"Low levels of BRCA1 protein expression predict a worse prognosis in stage I-II colon cancer.","authors":"Changzheng Du, Yifan Peng, Yiping He, Guoan Chen, Hao Chen","doi":"10.1177/1724600820986572","DOIUrl":null,"url":null,"abstract":"Background: BRCA1 and BRCA2 have been well studied for their roles in tumorigeneis, plus cancer diagnosis and treatment, but their prognostic value in colon cancer, especially for early-stage cancer, has not been fully illuminated. This study examined the expression levels of BRCA1 and BRCA2 proteins in sporadic colon cancer cases and investigated their value in prognosis.Methods: The expression levels of BRCA1 and BRCA2 in 275 colon cancer patients who underwent radical surgeries were assayed by immunohistochemical staining in dissected tumor samples. Also, its correlation with clinicopathological characteristics, disease-free survival, and overall survival was investigated.Results: Tumors with low expression levels of BRCA1, BRCA2, and both were 19.6%, 17.8%, and 6.5%, respectively. The levels of BRCA1/2 expression were not associated with clinicopathological parameters (gender, age, histological differentiation, and tumor node metastasis stage). Patients with low-levels of BRCA1 protein in their tumors demonstrated a lower chance of 5-year disease-free survival (55.6% vs. 69.7%, P=0.046), which was more obvious in the patients with stage I-II tumors without chemotherapy (52.6% vs. 82.6%, P=0.006). Neither BRCA1 nor BRCA2 affected overall survival in this cohort. Multivariate analysis revealed that pathologic stage and the level of BRCA1 protein were independent factors of long-term disease-free survival.Conclusion: This study highlights BRCA1 as an independent prognosticator of early-stage colon cancer.","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":"36 1","pages":"47-53"},"PeriodicalIF":2.3000,"publicationDate":"2021-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/1724600820986572","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Biological Markers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/1724600820986572","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/2/14 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}

引用次数: 3

Abstract

Background: BRCA1 and BRCA2 have been well studied for their roles in tumorigeneis, plus cancer diagnosis and treatment, but their prognostic value in colon cancer, especially for early-stage cancer, has not been fully illuminated. This study examined the expression levels of BRCA1 and BRCA2 proteins in sporadic colon cancer cases and investigated their value in prognosis.

Methods: The expression levels of BRCA1 and BRCA2 in 275 colon cancer patients who underwent radical surgeries were assayed by immunohistochemical staining in dissected tumor samples. Also, its correlation with clinicopathological characteristics, disease-free survival, and overall survival was investigated.

Results: Tumors with low expression levels of BRCA1, BRCA2, and both were 19.6%, 17.8%, and 6.5%, respectively. The levels of BRCA1/2 expression were not associated with clinicopathological parameters (gender, age, histological differentiation, and tumor node metastasis stage). Patients with low-levels of BRCA1 protein in their tumors demonstrated a lower chance of 5-year disease-free survival (55.6% vs. 69.7%, P=0.046), which was more obvious in the patients with stage I-II tumors without chemotherapy (52.6% vs. 82.6%, P=0.006). Neither BRCA1 nor BRCA2 affected overall survival in this cohort. Multivariate analysis revealed that pathologic stage and the level of BRCA1 protein were independent factors of long-term disease-free survival.

Conclusion: This study highlights BRCA1 as an independent prognosticator of early-stage colon cancer.

查看原文本刊更多论文

低水平的BRCA1蛋白表达预示着I-II期结肠癌的预后较差。

背景:BRCA1和BRCA2在肿瘤发生、癌症诊断和治疗中的作用已经得到了很好的研究，但它们在结肠癌，特别是早期癌症中的预后价值尚未得到充分阐明。本研究检测了散发性结肠癌病例中BRCA1和BRCA2蛋白的表达水平，并探讨了它们在预后中的价值。方法:应用免疫组化染色法检测275例根治性结肠癌患者解剖肿瘤标本中BRCA1和BRCA2的表达水平。并探讨其与临床病理特征、无病生存期及总生存期的相关性。结果:BRCA1、BRCA2和两者低表达的肿瘤分别为19.6%、17.8%和6.5%。BRCA1/2表达水平与临床病理参数(性别、年龄、组织学分化和肿瘤淋巴结转移分期)无关。肿瘤中BRCA1蛋白水平低的患者5年无病生存率较低(55.6%比69.7%，P=0.046)，未化疗的I-II期肿瘤患者5年无病生存率更低(52.6%比82.6%，P=0.006)。BRCA1和BRCA2均未影响该队列的总生存率。多因素分析显示，病理分期和BRCA1蛋白水平是影响长期无病生存的独立因素。结论:本研究强调BRCA1作为早期结肠癌的独立预后因子。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Biological Markers 医学-生物工程与应用微生物

CiteScore

4.10

自引率

0.00%

发文量

期刊介绍： IJBM is an international, online only, peer-reviewed Journal, which publishes original research and critical reviews primarily focused on cancer biomarkers. IJBM targets advanced topics regarding the application of biomarkers in oncology and is dedicated to solid tumors in adult subjects. The clinical scenarios of interests are screening and early diagnosis of cancer, prognostic assessment, prediction of the response to and monitoring of treatment.